Merck KGaA, Threshold win fast track for pancreatic cancer drug

FRANKFURT (Reuters) – Germany’s Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.

—> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail